Balapiravir

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

R1479 的前药，一种有效的、特异性的口服 HCV NS5B 聚合酶抑制剂。

The prodrug of R1479, a potent, specific and oral HCV NS5B polymerase inhibitor; demonstrates strong capacity to inhibit HCV replication in vitro and in vivo, without the rapid development of viral resistance.HCV Infection Phase 2 Discontinued.

——

After oral dosing of the CD-1 mice with 28.1 mg/kg of balapiravir (Ro 4588161; R1626), R1479 reaches a Cmax and a minimum concentration in plasma (Cmin) of 24.38 μM and 6.34 μM, respectively, at 2 h and 24 h postdosing.

R-1626 | R 1626 | Ro 4588161 | R1626 | Ro4588161 | Ro-4588161

Microbiology/Virology

HCV

HCV

Infection

HCV Infection

690270-29-2

494.4983

C21H30N6O8

>98% (HPLC)

DMSO: ≥ 100 mg/mL

CC(C(O[C@H]([C@@H]([C@]1(COC(C(C)C)=O)N=[N+]=[N-])OC(C(C)C)=O)[C@@H](O1)N(C=CC(N)=N2)C2=O)=O)C

Cytidine, 4'-C-azido-, 2',3',5'-tris(2-methylpropanoate)

(-20℃)

With Ice Pack

≥ 2 years